BioSpace News Archive

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presents data on sleep disturbances in Parkinson’s disease (PD) demonstrating the impact of OFF episodes, or reemergence of symptoms between doses of levodopa, on falling asleep and staying asleep.

KOL and Management to present on Monday, June 13, 2022 , @ 2:30pm ET.

Seqirus, a global leader in influenza prevention and a business of CSL Limited, announced the completion of an expansion to the company’s manufacturing facility in Holly Springs, N.C., supporting the formulation and fill-finish of its cell-based influenza vaccines in pre-filled syringes for global communities.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Karen A. Flynn, Senior Vice President and Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT), has been appointed to Quanterix’ Board of Directors effective June 6, 2022.

Third Harmonic Bio, a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe allergy and inflammation, today announced the appointment of Edward R. Conner, M.D., to chief medical officer.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Saira Ramasastry to the Company’s board of directors and as a member of the audit committee where she will bring to bear her more than 20 years of financial leadership.

NLS Pharmaceutics Ltd. announces that Chad C. Hellmann has been appointed to the position of Chief Financial Officer.

Pear Therapeutics Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using reSET ® at Six Months.

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that an international randomized phase 3 study (ASTRUM-005) of HANSIZHUANG (serplulimab), an anti-PD-1 mAb independently developed by Henlius, as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC) has been orally presented at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.